Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
Intelligent Bio Solutions (NASDAQ:INBS) was upgraded by analysts at
Wall
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
Intelligent Bio Solutions (NASDAQ:INBS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules